Home » Newsletters » BioWorld Science

BioWorld Science

March 16, 2007

View Archived Issues

Snapshots on AMD-11070, a novel small-molecule CXCR4 inhibitor

Immune responses expanded with Remune(R) during HIV treatment interruption

Atorvastatin may reduce cardiovascular events more than simvastatin

Enterotoxigenic Escherichia coli vaccine reduces diarrhea severity in double-blind trial

Astellas Pharma updates clinical progress of YM-155

Recent Lilly and Merck patents describe new antidiabetic agents

Novel antiinfective agents disclosed in recent patent literature

Recent patents cover new therapeutic agents for cancer

Novel treatments for inflammatory disorders claimed in recent patents

Roche to terminate MAXY-VII collaboration with Maxygen

Adherex outlines achievements of 2006, updates goals for 2007

IRB approval for phase III study of crofelemer in HIV-associated diarrhea

FDA awards orphan drug status to cethromycin for anthrax infection

Curis selects CUDC-101 from targeted cancer drug development platform

Tragara closes Series A financing to support oncology and inflammatory programs

Nektar advances PEG-irinotecan into phase I

Avigen cleared to begin phase II with AV-650 for spasticity and muscle spasms

Difimicin cleared to advance into phase III

Curalogic initiates phase III trial for oral ragweed therapy

GV-1001 studied with chemotherapy for inoperable pancreatic cancer

TG-1042 for cutaneous B-cell lymphoma in phase II trial

C1-INH meets primary endpoint in acute HAE study

Phase II results for Aridol in COPD

Identification of a novel cdk5/p25 inhibitor potentially useful for Alzheimer's disease

Transtec more effective and better tolerated than morphine

Japanese launch for Copegus in chronic hepatitis C

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...